Knight Therapeutics relaunches Orgovyx in Canada

Executive Summary

• Knight Therapeutics announced the relaunch of Orgovyx® (relugolix) in Canada, expanding its availability across most provinces following successful pCPA negotiations.
• The product is the first oral GnRH receptor antagonist approved by Health Canada for advanced prostate cancer and taps into a Canadian market valued at over $200 million with an 8% five‑year CAGR.
• Knight’s CEO Samira Sakhia highlighted the strategic fit of Orgovyx within the company’s oncology portfolio and its potential to drive revenue growth (approx. $1.2 M sales in Canada in 2024).

Key Details

• License & Supply Agreements: Exclusive licence and supply agreements with Sumitomo Pharma America Inc. (SMPA) cover Myfembree, Orgovyx, and vibegron for the Canadian market.
• Asset Purchase: Knight acquired certain mature products from SMPA under an asset purchase agreement.
• Regulatory Milestones:
• Health Canada approval received in October 2023.
• Initial launch occurred in March 2024.
• Pan‑Canadian Pharmaceutical Alliance (pCPA) negotiations concluded successfully in February 2025, enabling public listing in most provinces.
• Market Context: Canadian GnRH agonist/antagonist market for prostate cancer is valued at >$200 M and growing at a 5‑year CAGR of ~8%.
• Sales Performance: Orgovyx sales in Canada were approximately $1.2 million in 2024 (per IQVIA).
• Strategic Fit: Orgovyx complements Knight’s existing oncology assets, notably Trelstar, allowing leverage of current commercial infrastructure.

Notable Quotes

“Orgovyx offers health care professionals a convenient oral alternative to rapidly suppress testosterone production for patients with prostate cancer… It is synergistic with our existing oncology portfolio and will allow Knight to leverage our existing infrastructure.” – Samira Sakhia, President & CEO, Knight Therapeutics.